
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial
Investing.com -- Shares of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) plunged 33.5% following the company’s announcement that the U.S. Food and Drug Administration (FDA) requires a confirmatory Phase 3 trial for apraglutide, potentially delaying the drug’s approval for patients with short bowel syndrome (SBS) with intestinal failure (IF) who depend on parenteral support.The biotechnology fi ...